Navigation Links
QMed, Inc. Receives NASDAQ Letter
Date:12/24/2007

EATONTOWN, N.J., Dec. 24 /PRNewswire-FirstCall/ -- QMed, Inc., (Nasdaq: QMED) today announced that it has received a letter from Nasdaq indicating, that for the last 30 business days, the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4310(c)(4) (the "Rule"). Therefore, in accordance with Marketplace Rule 4310(c) (8) (D), the Company will be provided 180 calendar days, or until June 16, 2008 to regain compliance. If, at any time before June 16, 2008, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will be provided written notification that it complies with the Rule.

If compliance with this Rule cannot be demonstrated by June 16, 2008, Nasdaq Staff will determine whether the Company meets The Nasdaq Capital Market initial listing criteria as set forth in Marketplace Rule 4310(c), except for the bid price requirement. If it meets the initial listing criteria, the Company will be notified that it will be granted an additional 180 calendar day compliance period. If the Company is not eligible for an additional compliance period, the Company will receive written notification from Nasdaq Staff that the Company's securities will be delisted. At that time, the Company may appeal the Staff's determination to delist its securities to a Listing Qualifications Panel.

About QMed, Inc.

QMed has developed evidence-based clinical information management systems for use by health plan customers. The QMed systems incorporate Disease Management services to patients and decision support to physicians. The Company's subsidiaries have specialized in serving high-risk populations of Medicare beneficiaries.

Except for historical information contained herein, matters discussed in this news release are forward-looking statements that involve risks and uncertainties. They include but are not limited to those relating to the timely implementation of programs, the impact of business and operational conditions, competitive product introductions, acceptance and pricing, and those risks detailed in the Company's filings with the Securities and Exchange Commission (SEC). Actual results may differ materially from any forward- looking statements due to these risks and uncertainties.

Contact: William Schmitt, QMed, Inc. -- 732-544-5544 x1112


'/>"/>
SOURCE QMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
2. QMed, Inc. Extends Agreement & Receives $550,000 Performance Bonus
3. QMed, Inc. Reports Third Quarter Results
4. QMed, Inc. Retains Lazard Middle Market
5. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... is growing as it continues developing an ANSI-approved, consensus-based American National Standard ... which plans to publish the first ANSI-approved GMP standard for dietary supplements ...
(Date:3/29/2017)... , ... March 29, 2017 , ... HealthCareMandA.com will host ... April 20, 2017, at 1:00 PM ET. A recording of the webinar will also ... Webinar Series. , Home health and hospice companies are still popular targets for healthcare ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") ... financial results for the year ended December 31, ... 2017. The results are being released later than ... statements will include the operations and balances of ... 2016.  This release and filing date meets TSX ...
(Date:3/28/2017)... "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and ... market trends of the Chemotherapy Induced Neutropenia for the seven major ... ( France , Germany ... UK) and Japan , as well as rest ... world (RoW). The Report covers the therapeutics market revenue, ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer ... on the various indicators and trend analysis related ... drugs in mainstream pharmaceutical market in US. The ... for the growth on cancer generics drugs in ... in saving of billions of dollars for various ...
Breaking Medicine Technology: